{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:46:04Z","timestamp":1793965564152,"version":"4.8.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70113515"],"award-info":[{"award-number":["70113515"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["259332240"],"award-info":[{"award-number":["259332240"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["70114336"],"award-info":[{"award-number":["70114336"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004376","name":"Terry Fox Research Institute","doi-asserted-by":"publisher","award":["10017712"],"award-info":[{"award-number":["10017712"]}],"id":[{"id":"10.13039\/501100004376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005677","name":"Jos\u00e9 Carreras Leuk\u00e4mie-Stiftung","doi-asserted-by":"publisher","award":["Project-ID DJCLS 01ZI\/2022"],"award-info":[{"award-number":["Project-ID DJCLS 01ZI\/2022"]}],"id":[{"id":"10.13039\/501100005677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018857","name":"International Myeloma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.ccell.2023.02.008","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T10:32:27Z","timestamp":1678357947000},"page":"711-725.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":303,"title":["The pre-existing T\u00a0cell landscape determines the response to bispecific T\u00a0cell engagers in multiple myeloma patients"],"prefix":"10.1016","volume":"41","author":[{"given":"Mirco J.","family":"Friedrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Kehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Steiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kilian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie","family":"Leblay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjan","family":"Maity","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Sankowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungwoo","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Weinhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Rippe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Bunse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Platten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Steffen","family":"Raab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar J.","family":"Bahlis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2023.02.008_bib1","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T\u00a0cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ccell.2023.02.008_bib2","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T\u00a0cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ccell.2023.02.008_bib3","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41420-022-00893-x","article-title":"A single-cell transcriptomic landscape of innate and adaptive intratumoral immunity in triple negative breast cancer during chemo- and immunotherapies","volume":"8","author":"Carpen","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ccell.2023.02.008_bib4","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41591-021-01323-8","article-title":"A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer","volume":"27","author":"Bassez","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2023.02.008_bib5","first-page":"108","article-title":"Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T\u00a0cells during anti-PD-1 therapy in lung cancer","volume":"3","author":"Liu","year":"2021","journal-title":"Nat. Can. (Que.)"},{"key":"10.1016\/j.ccell.2023.02.008_bib6","doi-asserted-by":"crossref","first-page":"7870","DOI":"10.1038\/s41586-021-03704-y","article-title":"Phenotype, specificity and avidity of antitumour CD8+ T\u00a0cells in melanoma","volume":"596","author":"Oliveira","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2023.02.008_bib7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41591-018-0266-5","article-title":"Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers","volume":"25","author":"Scheper","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2023.02.008_bib8","first-page":"493","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat. Can. (Que.)"},{"key":"10.1016\/j.ccell.2023.02.008_bib9","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1038\/s41467-021-22804-x","article-title":"Co-evolution of tumor and immune cells during progression of multiple myeloma","volume":"12","author":"Liu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2023.02.008_bib10","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1038\/s41591-018-0269-2","article-title":"Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma","volume":"24","author":"Ledergor","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2023.02.008_bib11","doi-asserted-by":"crossref","first-page":"6960","DOI":"10.1038\/s41467-021-26951-z","article-title":"Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics","volume":"12","author":"Tirier","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2023.02.008_bib12","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41590-021-00931-3","article-title":"The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape","volume":"22","author":"de Jong","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ccell.2023.02.008_bib13","article-title":"Early alterations in stem-like\/marrow-resident T\u00a0cells and innate and myeloid cells in preneoplastic gammopathy","volume":"5","author":"Bailur","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.ccell.2023.02.008_bib14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41556-019-0439-6","article-title":"Combined single-cell and spatial transcriptomics reveal the molecular, cellular and spatial bone marrow niche organization","volume":"22","author":"Baccin","year":"2020","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ccell.2023.02.008_bib15","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3389\/fcell.2021.622519","article-title":"Connecting the dots: resolving the bone marrow niche heterogeneity","volume":"9","author":"Dolgalev","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ccell.2023.02.008_bib16","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.cell.2019.04.040","article-title":"A cellular taxonomy of the bone marrow stroma in homeostasis and leukemia","volume":"177","author":"Baryawno","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2023.02.008_bib17","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","article-title":"Clonal replacement of tumor-specific T\u00a0cells following PD-1 blockade","volume":"25","author":"Yost","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2023.02.008_bib18","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T\u00a0cell states associated with response to checkpoint immunotherapy in melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2023.02.008_bib19","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2018.11.043","article-title":"Dysfunctional CD8 T\u00a0cells form a proliferative, dynamically regulated compartment within human melanoma","volume":"176","author":"Li","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2023.02.008_bib20","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T\u00a0cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"Mcgranahan","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ccell.2023.02.008_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abi8800","article-title":"Lack of CD8+T cell effector differentiation during priming mediates checkpoint blockade resistance in non-small cell lung cancer","volume":"6","author":"Horton","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.ccell.2023.02.008_bib22","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41571-022-00620-6","article-title":"Clinical relevance of tumour-associated macrophages","volume":"19","author":"Pittet","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ccell.2023.02.008_bib23","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1158\/1078-0432.CCR-14-1860","article-title":"Immune escape mechanisms as a guide for cancer immunotherapy","volume":"21","author":"Beatty","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2023.02.008_bib24","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.ccell.2023.02.008_bib25","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1182\/bloodadvances.2020002393","article-title":"Teclistamab is an active T\u00a0cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma","volume":"4","author":"Pillarisetti","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.ccell.2023.02.008_bib26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood-2020-138831","article-title":"Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed and\/or refractory multiple myeloma (RRMM)","volume":"136","author":"Garfall","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2023.02.008_bib27","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2020-134063","article-title":"A phase 1 first in human (FIH) study of AMG 701, an anti-B-cell maturation antigen (BCMA) half-life extended (HLE) BiTE\u00ae (bispecific T-cell engager) molecule, in relapsed\/refractory (RR) multiple myeloma (MM)","volume":"136","author":"Harrison","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2023.02.008_bib28","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.8006","article-title":"Efficacy and Safety of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma (MM)","volume":"39","author":"Bahlis","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2023.02.008_bib29","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.18632\/oncotarget.27792","article-title":"T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma","volume":"11","author":"Verkleij","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.ccell.2023.02.008_bib30","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/bloodadvances.2021004418","article-title":"Single- and double-hit events in genes encoding immune targets before and after T\u00a0cell-engaging antibody therapy in MM","volume":"5","author":"Truger","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.ccell.2023.02.008_bib31","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1158\/1078-0432.CCR-19-1714","article-title":"Marrow-infiltrating regulatory T\u00a0cells correlate with the presence of dysfunctional CD4\u00fePD-1\u00fe cells and inferior survival in patients with newly diagnosed multiple myeloma","volume":"26","author":"Alrasheed","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2023.02.008_bib32","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2005-08-3101","article-title":"Dysfunctional T regulatory cells in multiple myeloma","volume":"107","author":"Prabhala","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2023.02.008_bib33","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0145-2126(01)00192-8","article-title":"Relationship between CD4+\/CD8+ T\u00a0cell ratio and T\u00a0cell activation in multiple myeloma: reference to IL-16","volume":"26","author":"Koike","year":"2002","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ccell.2023.02.008_bib34","first-page":"129","article-title":"Multiple myeloma: altered CD4\/CD8 ratio in bone marrow","volume":"75","author":"Redoglia","year":"1990","journal-title":"Haematologica"},{"key":"10.1016\/j.ccell.2023.02.008_bib35","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1038\/s41590-020-0791-5","article-title":"Two subsets of stem-like CD8+ memory T\u00a0cell progenitors with distinct fate commitments in humans","volume":"21","author":"Galletti","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ccell.2023.02.008_bib36","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2023.02.008_bib37","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1182\/blood-2018-99-118970","article-title":"Preclinical characterization of AFM26, a novel B cell maturation antigen (BCMA)-Directed tetravalent bispecific antibody for high affinity retargeting of NK cells against myeloma","volume":"132","author":"Ross","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2023.02.008_bib38","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1182\/blood-2019-128749","article-title":"CTX-8573, an innate-cell engager targeting BCMA, is a highly potent multispecific antibody for the treatment of multiple myeloma","volume":"134","author":"Watkins-Yoon","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2023.02.008_bib39","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1158\/1535-7163.MCT-18-1216","article-title":"Anti-GPRC5D\/CD3 bispecific T-cell-redirecting antibody for the treatment of multiple myeloma","volume":"18","author":"Kodama","year":"2019","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ccell.2023.02.008_bib40","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/blood.2019003342","article-title":"A T-cell\u2013redirecting bispecific G-protein\u2013coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma","volume":"135","author":"Pillarisetti","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2023.02.008_bib41","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1158\/1078-0432.CCR-19-2299","article-title":"Preclinical activity of JNJ-7957, a novel BCMA \u00d7CD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab","volume":"26","author":"Frerichs","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2023.02.008_bib42","doi-asserted-by":"crossref","first-page":"v808","DOI":"10.1093\/annonc\/mdz269.038","article-title":"A Novel bispecific BCMAxCD3 T\u00a0cell-engaging antibody that treat multiple myeloma (MM) with minimal cytokine secretion","volume":"30","author":"Li","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2023.02.008_bib43","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.3324\/haematol.2019.242453","article-title":"Bi38-3 is a novel CD38\/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma","volume":"106","author":"Fayon","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.ccell.2023.02.008_bib44","doi-asserted-by":"crossref","first-page":"8045","DOI":"10.1200\/JCO.2017.35.15_suppl.8045","article-title":"AFM26 is a novel, highly potent BCMA\/CD16A-directed bispecific antibody for high affinity NK-cell engagement in multiple myeloma","volume":"35","author":"Gantke","year":"2017","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2023.02.008_bib45","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2023.02.008_bib46","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1158\/2643-3230.BCD-21-0028","article-title":"Bispecific antibodies in multiple myeloma: present and future","volume":"2","author":"Lancman","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.ccell.2023.02.008_bib47","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.immuni.2020.11.005","article-title":"Comprehensive profiling of an aging immune system reveals clonal GZMK+ CD8+ T\u00a0cells as conserved hallmark of inflammaging","volume":"54","author":"Mogilenko","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.ccell.2023.02.008_bib48","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2021-153863","article-title":"Characterization of T-cell exhaustion in rapid progressing multiple myeloma using cross center Scrna-seq study","volume":"138","author":"Pilcher","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2023.02.008_bib49","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41592-021-01346-6","article-title":"CellRank for directed single-cell fate mapping","volume":"19","author":"Lange","year":"2022","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ccell.2023.02.008_bib50","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/ncb3493","article-title":"Human haematopoietic stem cell lineage commitment is a continuous process","volume":"19","author":"Velten","year":"2017","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ccell.2023.02.008_bib51","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"MRNA destabilization by BTG1 and BTG2 maintains T\u00a0cell quiescence","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ccell.2023.02.008_bib52","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","article-title":"Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape\u2013driven relapse in multiple myeloma","volume":"1","author":"Fern\u00e1ndez de Larrea","year":"2020","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.ccell.2023.02.008_bib53","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/eji.201343718","article-title":"Tumor-specific CD4+ T\u00a0cells maintain effector and memory tumor-specific CD8+ T\u00a0cells","volume":"44","author":"Church","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ccell.2023.02.008_bib54","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","article-title":"CD4+ T\u00a0cell help in cancer immunology and immunotherapy","volume":"18","author":"Borst","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ccell.2023.02.008_bib55","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/2643-3230.BCD-21-0038","article-title":"Tumor burden limits bispecific antibody efficacy through T-cell exhaustion averted by concurrent cytotoxic therapy","volume":"2","author":"Meermeier","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.ccell.2023.02.008_bib56","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1158\/2643-3230.BCD-21-0059","article-title":"Bortezomib induces immunogenic cell death in multiple myeloma","volume":"2","author":"Zitvogel","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.ccell.2023.02.008_bib57","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1158\/2643-3230.BCD-21-0047","article-title":"Bortezomib induces anti-multiple myeloma immune response mediated by cGAS\/STING pathway activation","volume":"2","author":"Gulla","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.ccell.2023.02.008_bib58","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1290\/0508054.1","article-title":"Gamma-radiation upregulates MHC class I\/II and ICAM-I molecules in multiple myeloma cell lines and primary tumors","volume":"42","author":"Chiriva-Internati","year":"2006","journal-title":"In\u00a0Vitro Cell. Dev. Biol. Anim."},{"key":"10.1016\/j.ccell.2023.02.008_bib59","doi-asserted-by":"crossref","first-page":"20140291","DOI":"10.1098\/rstb.2014.0291","article-title":"Estimating T-cell repertoire diversity: limitations of classical estimators and a new approach","volume":"370","author":"Laydon","year":"2015","journal-title":"Philos Trans R Soc Lond B Biol Sci."},{"key":"10.1016\/j.ccell.2023.02.008_bib60","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41592-021-01153-z","article-title":"Ultra-high-throughput single-cell RNA sequencing and perturbation screening with combinatorial fluidic indexing","volume":"18","author":"Datlinger","year":"2021","journal-title":"Nat. Methods"}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610823000363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610823000363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:11:45Z","timestamp":1761523905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610823000363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1535610823000363"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2023.02.008","relation":{},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The pre-existing T\u00a0cell landscape determines the response to bispecific T\u00a0cell engagers in multiple myeloma patients","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2023.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}